Juan Quiros - Establishment Labs CEO, Director
| ESTA Stock | USD 43.08 0.47 1.10% |
CEO
Mr. Juan Jose Chacon Quiros is Chief Executive Officer, Director of the Company. Mr. Chacon Quiros founded Establishment Labs, S.A. in 2004 and was a director and the Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacon Quiros was involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America, and prior to that as Business Development Manager of a plastic and reconstructive surgery clinic in Costa Rica. He also served as President of the Rugby Federation of Costa Rica from 2009 to 2015.
| Age | 51 |
| Address | Building B15 and 25, Alajuela, Costa Rica |
| Phone | 506 2434 2400 |
| Web | https://www.establishmentlabs.com |
Latest Insider Transactions
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1207) % which means that it has lost $0.1207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2345) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.29. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.9 M, whereas Total Assets are forecasted to decline to about 150.6 M.Similar Executives
| Found 11 records | CEO Age | ||
| Kathleen Skarvan | Electromed | 68 | |
| Glendon French | Pulmonx Corp | 62 | |
| Albert DaCosta | Paragon 28 | 51 | |
| Damien McDonald | LivaNova PLC | 59 | |
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Vladimir Makatsaria | LivaNova PLC | 51 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Gary Maharaj | SurModics | 61 | |
| Charles II | Apyx Medical | 58 | |
| Joel Becker | Neuropace | 56 | |
Management Performance
| Return On Equity | -2.23 | ||||
| Return On Asset | -0.12 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juan Quiros, CEO, Director | ||
| Heather Brennan, Head Operations | ||
| Roberto Mezerville, Chief Officer | ||
| Paul Rodio, Chief Officer | ||
| Jeff Ehrhard, Senior America | ||
| Ivan Bilic, Senior OUS | ||
| Ross Mansbach, General Officer | ||
| Jeffrey Bettinger, Global People | ||
| Neeta Toprani, Corporate Secretary | ||
| Rosalyn dIncelli, Medical Clinical | ||
| Rajbir Denhoy, Chief Officer | ||
| Filippo Caldini, President | ||
| Salvador Dada, Chief Officer | ||
| Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.46) % | ||||
| Operating Margin | (0.33) % | ||||
| Current Valuation | 1.36 B | ||||
| Shares Outstanding | 28.76 M | ||||
| Shares Owned By Insiders | 11.27 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 5.12 M | ||||
| Price To Earning | (20.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Establishment Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Establishment Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Establishment Labs Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Establishment Labs Holdings Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Revenue Per Share 5.58 | Quarterly Revenue Growth 0.045 | Return On Assets (0.12) | Return On Equity (2.23) |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.